{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:29:28Z","timestamp":1785493768151,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"am","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["RO1DA038965"],"award-info":[{"award-number":["RO1DA038965"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["RO1DA046049"],"award-info":[{"award-number":["RO1DA046049"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA023356"],"award-info":[{"award-number":["T32DA023356"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.josat.2025.209742","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:26:02Z","timestamp":1751563562000},"page":"209742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Perspectives on medication for opioid use disorder (MOUD) access and service delivery among a community sample of people who use opioids in Los Angeles"],"prefix":"10.1016","volume":"176","author":[{"given":"Maria","family":"Bolshakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey A.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhi S.","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky N.","family":"Bluthenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.josat.2025.209742_bb0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13722-021-00244-8","article-title":"Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: A systematic review","volume":"16","author":"Adams","year":"2021","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.josat.2025.209742_bb0015","series-title":"Provisional drug overdose death counts","author":"Ahmad","year":"2022"},{"issue":"4","key":"10.1016\/j.josat.2025.209742_bb0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/08897077.2019.1640833","article-title":"Underutilization of medications to treat opioid use disorder: What role does stigma play?","volume":"40","author":"Allen","year":"2019","journal-title":"Substance Abuse"},{"issue":"6","key":"10.1016\/j.josat.2025.209742_bb0025","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","article-title":"The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era","volume":"47","author":"Amram","year":"2021","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.josat.2025.209742_bb0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ajad.13069","article-title":"Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine\/naloxone","volume":"30","author":"Antoine","year":"2021","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.josat.2025.209742_bb0035","series-title":"Lowering the barriers to medication treatment for people with opioid use disorder: Evidence for a low-threshold approach","author":"Aronowitz","year":"2022"},{"issue":"3","key":"10.1016\/j.josat.2025.209742_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: The foundation of recovery","volume":"31","author":"Bart","year":"2012","journal-title":"Journal of Addictive Diseases"},{"issue":"2","key":"10.1016\/j.josat.2025.209742_bb0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1353\/hah.2011.0019","article-title":"Methadone maintenance treatment: Disciplining the \u201caddict\u201d","volume":"13","author":"Bennett","year":"2011","journal-title":"Health & History: Journal of the Australian & New Zealand Society for the History of Medicine"},{"key":"10.1016\/j.josat.2025.209742_bb0050","series-title":"Grounded theory: A practical guide","author":"Birks","year":"2015"},{"key":"10.1016\/j.josat.2025.209742_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107932","article-title":"Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs","volume":"211","author":"Bluthenthal","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209742_bb0060","first-page":"212","article-title":"Multimethod research from targeted sampling to HIV risk environments","volume":"157","author":"Bluthenthal","year":"1995","journal-title":"NIDA Research Monograph"},{"key":"10.1016\/j.josat.2025.209742_bb0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2016.03.003","article-title":"The future of opioid agonist therapies in Ukraine: A qualitative assessment of multilevel barriers and ways forward to promote retention in treatment","volume":"66","author":"Bojko","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.josat.2025.209742_bb0070","doi-asserted-by":"crossref","first-page":"556","DOI":"10.15288\/jsad.2020.81.556","article-title":"Addressing the syndemic of HIV, hepatitis C, overdose, and COVID-19 among people who use drugs: The potential roles for decriminalization and safe supply","volume":"81","author":"Bonn","year":"2020","journal-title":"Journal of Studies on Alcohol and Drugs"},{"key":"10.1016\/j.josat.2025.209742_bb0080","series-title":"Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction","author":"Center for Substance Abuse Treatment","year":"2004"},{"issue":"1","key":"10.1016\/j.josat.2025.209742_bb0085","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/08897077.2021.2010251","article-title":"\u201cI wanted something that was more flexible\u201d: A qualitative study of patient preferences on choosing buprenorphine over methadone in a large, safety-net hospital opioid treatment program","volume":"43","author":"Checkley","year":"2022","journal-title":"Substance Abuse"},{"issue":"7","key":"10.1016\/j.josat.2025.209742_bb0090","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1197\/j.aem.2007.04.005","article-title":"Identifying injection drug users at risk of nonfatal overdose","volume":"14","author":"Coffin","year":"2007","journal-title":"Academic Emergency Medicine"},{"issue":"11","key":"10.1016\/j.josat.2025.209742_bb0095","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2105\/AJPH.85.11.1577","article-title":"Regulating controversial programs for unpopular people: Methadone maintenance and syringe exchange programs","volume":"85","author":"Des Jarlais","year":"1995","journal-title":"American Journal of Public Health"},{"issue":"9","key":"10.1016\/j.josat.2025.209742_bb0100","first-page":"1573","article-title":"Managing opioid addiction with buprenorphine","volume":"73","author":"Donaher","year":"2006","journal-title":"American Family Physician"},{"issue":"2","key":"10.1016\/j.josat.2025.209742_bb0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2025.209742_bb0110","author":"European Monitoring Centre for Drugs and Drug Addiction"},{"issue":"2","key":"10.1016\/j.josat.2025.209742_bb0115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/10826084.2017.1310247","article-title":"\u201cI was not sick and I didn\u2019t need to recover\u201d: Methadone maintenance treatment (MMT) as a refuge from criminalization","volume":"53","author":"Frank","year":"2018","journal-title":"Substance Use & Misuse"},{"issue":"1","key":"10.1016\/j.josat.2025.209742_bb0120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt\u2019s like \u2018liquid handcuffs\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduction Journal"},{"issue":"7","key":"10.1016\/j.josat.2025.209742_bb0125","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/add.15805","article-title":"Mortality and negative outcomes of opioid use and opioid use disorder: A 6-year follow-up study","volume":"117","author":"Gholami","year":"2022","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.josat.2025.209742_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0217","article-title":"The burden of opioid-related mortality in the United States","volume":"1","author":"Gomes","year":"2018","journal-title":"JAMA Network Open"},{"issue":"7","key":"10.1016\/j.josat.2025.209742_bb0135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.josat.2025.209742_bb0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2025.209742_bb0145","series-title":"Scaling up medications for opioid use disorder in Kentucky: Qualitative perspectives of treatment organizations","first-page":"rs","author":"Knudsen","year":"2024"},{"key":"10.1016\/j.josat.2025.209742_bb0150","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11524-010-9486-9","article-title":"Comparing respondent-driven sampling and targeted sampling methods of recruiting injection drug users in San Francisco","volume":"87","author":"Kral","year":"2010","journal-title":"Journal of Urban Health"},{"key":"10.1016\/j.josat.2025.209742_bb0160","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: A rapid review","volume":"35","author":"Mackey","year":"2020","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2025.209742_bb0165","series-title":"Medications for opioid use disorder save lives","article-title":"The effectiveness of medication-based treatment for opioid use disorder","author":"Mancher","year":"2019"},{"key":"10.1016\/j.josat.2025.209742_bb0170","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1016\/j.josat.2025.209742_bb0175","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1093\/cid\/ciaa008","article-title":"Bacterial infections associated with substance use disorders, large cohort of United States hospitals, 2012\u20132017","volume":"71","author":"McCarthy","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.josat.2025.209742_bb0190","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1521\/aeap.2007.19.2.124","article-title":"Reduction in injection\u2013related HIV risk after 6 months in a low-threshold methadone treatment program","volume":"19","author":"Millson","year":"2007","journal-title":"AIDS Education and Prevention: Official Publication of the International Society for AIDS Education"},{"key":"10.1016\/j.josat.2025.209742_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2020.106740","article-title":"Short communication: Systematic review on effectiveness of micro-induction approaches to buprenorphine initiation","volume":"114","author":"Moe","year":"2021","journal-title":"Addictive Behaviors"},{"issue":"10","key":"10.1016\/j.josat.2025.209742_bb0200","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1176\/appi.ajp.2018.17101112","article-title":"Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses, and crime","volume":"175","author":"Molero","year":"2018","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.josat.2025.209742_bb0205","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jsat.2019.01.019","article-title":"Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support","volume":"100","author":"Muthulingam","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.josat.2025.209742_bb0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000346674","article-title":"The experience of long-term opiate maintenance treatment and reported barriers to recovery: A qualitative systematic review","volume":"19","author":"Notley","year":"2013","journal-title":"European Addiction Research"},{"issue":"9","key":"10.1016\/j.josat.2025.209742_bb0215","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","article-title":"Standards for reporting qualitative research: A synthesis of recommendations","volume":"89","author":"O\u2019Brien","year":"2014","journal-title":"Academic Medicine"},{"issue":"3","key":"10.1016\/j.josat.2025.209742_bb0230","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1503\/cmaj.74018","article-title":"Buprenorphine-naloxone \u201cmicrodosing\u201d: An alternative induction approach for the treatment of opioid use disorder in the wake of North America\u2019s increasingly potent illicit drug market","volume":"192","author":"Randhawa","year":"2020","journal-title":"CMAJ: Canadian Medical Association journal = journal de l\u2019Association medicale canadienne"},{"issue":"5","key":"10.1016\/j.josat.2025.209742_bb0235","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid","volume":"39","author":"Samples","year":"2020","journal-title":"Health Affairs (Project Hope)"},{"issue":"5","key":"10.1016\/j.josat.2025.209742_bb0240","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s11606-021-07249-8","article-title":"Buprenorphine telehealth treatment initiation and follow-up during COVID-19","volume":"37","author":"Samuels","year":"2022","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2025.209742_bb0245","article-title":"Supervised dosing with a long-acting opioid medication in the management of opioid dependence","volume":"4","author":"Saulle","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.josat.2025.209742_bb0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13722-020-00186-7","article-title":"Six-month retention and changes in quality of life and substance use from a low-threshold methadone maintenance therapy programme in Durban, South Africa","volume":"15","author":"Scheibe","year":"2020","journal-title":"Addiction Science & Clinical Practice"},{"issue":"5","key":"10.1016\/j.josat.2025.209742_bb0255","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/10550490802268835","article-title":"Attitudes toward buprenorphine and methadone among opioid-dependent individuals","volume":"17","author":"Schwartz","year":"2008","journal-title":"American Journal on Addictions"},{"issue":"8","key":"10.1016\/j.josat.2025.209742_bb0260","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1080\/10826084.2021.1914109","article-title":"Ending the chase: Experiences of rural individuals with opioid use disorder","volume":"56","author":"Scorsone","year":"2021","journal-title":"Substance Use & Misuse"},{"issue":"2","key":"10.1016\/j.josat.2025.209742_bb0265","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/dar.13394","article-title":"Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series","volume":"41","author":"Shearer","year":"2022","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.josat.2025.209742_bb0270","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: Buprenorphine experiences in an era of illicit fentanyl","volume":"74","author":"Silverstein","year":"2019","journal-title":"International Journal of Drug Policy"},{"issue":"S2","key":"10.1016\/j.josat.2025.209742_bb0275","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","article-title":"The methadone manifesto: Treatment experiences and policy recommendations from methadone patient activists","volume":"112","author":"Simon","year":"2022","journal-title":"American Journal of Public Health"},{"issue":"6","key":"10.1016\/j.josat.2025.209742_bb0280","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/10826084.2024.2306221","article-title":"Characterizing opioid withdrawal experiences and consequences among a community sample of people who use opioids","volume":"59","author":"Simpson","year":"2024","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.josat.2025.209742_bb0285","article-title":"Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl","volume":"1\u20138","author":"Spadaro","year":"2022","journal-title":"Clinical Toxicology"},{"key":"10.1016\/j.josat.2025.209742_bb0290","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.josat.2025.209742_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108651","article-title":"Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs\u2019 perspectives of and experiences with the extramedical use and diversion of buprenorphine","volume":"135","author":"Sud","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2025.209742_bb0305","first-page":"45","article-title":"Sample size and grounded theory","volume":"5","author":"Thomson","year":"2011","journal-title":"Journal of Administration and Governance"},{"issue":"14","key":"10.1016\/j.josat.2025.209742_bb0310","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1080\/10826084.2019.1653324","article-title":"Patient barriers and facilitators to medications for opioid use disorder in primary care","volume":"54","author":"Tofighi","year":"2019","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.josat.2025.209742_bb0315","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2016.02.009","article-title":"Patients\u2019 beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification","volume":"66","author":"Uebelacker","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.josat.2025.209742_bb0320","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl","volume":"16","author":"Varshneya","year":"2021","journal-title":"Journal of Addiction Medicine"},{"issue":"2","key":"10.1016\/j.josat.2025.209742_bb0325","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.josat.2025.209742_bb0330","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2307\/800824","article-title":"Targeted sampling: Options for the study of hidden populations*","volume":"36","author":"Watters","year":"1989","journal-title":"Social Problems"},{"key":"10.1016\/j.josat.2025.209742_bb0335","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","article-title":"Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis","volume":"160","author":"Yarborough","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209742_bb0340","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drugalcdep.2018.05.027","article-title":"Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine","volume":"190","author":"Zelenev","year":"2018","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:40:39Z","timestamp":1762652439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925001213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":60,"alternative-id":["S2949875925001213"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209742","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives on medication for opioid use disorder (MOUD) access and service delivery among a community sample of people who use opioids in Los Angeles","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"209742"}}